Abstract
Vascular embolisation agents are particles or fluids that can be released into the bloodstream through a catheter to mechanically and/or biologically occlude the target vessel, either temporarily or permanently. This definition excludes vessel-blocking agents or devices such as balloons and coils, which are positioned at the target site, as opposed to released in the bloodstream. Vascular embolisation agents are available as solids, liquids and suspensions. Careful selection of the agent based on the size and calibre of the target vessel ensures that the occlusion is confined to the desired site. In this review, we discuss the 2 main categories of embolisation agents: particles (either non-spherical or microspherical), which are the most widely used; and liquids (glues, gels, sclerosing agents and viscous emulsions). For each agent, we review the characteristics, mechanisms of action, main indications and modalities of use, advantages and drawbacks. The use of embolisation in clinical practice requires a thorough understanding of the behaviour (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are being developed.
Keywords: Interventional radiology, endovascular embolisation, occluding agents, resorbable embolic material, particles, surgical glue
Current Vascular Pharmacology
Title: Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues
Volume: 7 Issue: 2
Author(s): Romaric Loffroy, Boris Guiu, Jean-Pierre Cercueil and Denis Krause
Affiliation:
Keywords: Interventional radiology, endovascular embolisation, occluding agents, resorbable embolic material, particles, surgical glue
Abstract: Vascular embolisation agents are particles or fluids that can be released into the bloodstream through a catheter to mechanically and/or biologically occlude the target vessel, either temporarily or permanently. This definition excludes vessel-blocking agents or devices such as balloons and coils, which are positioned at the target site, as opposed to released in the bloodstream. Vascular embolisation agents are available as solids, liquids and suspensions. Careful selection of the agent based on the size and calibre of the target vessel ensures that the occlusion is confined to the desired site. In this review, we discuss the 2 main categories of embolisation agents: particles (either non-spherical or microspherical), which are the most widely used; and liquids (glues, gels, sclerosing agents and viscous emulsions). For each agent, we review the characteristics, mechanisms of action, main indications and modalities of use, advantages and drawbacks. The use of embolisation in clinical practice requires a thorough understanding of the behaviour (rheology and vascular topology) and biocompatibility of each agent. To improve the accuracy of targeting, we need new, more sophisticated, bioactive agents, which are being developed.
Export Options
About this article
Cite this article as:
Loffroy Romaric, Guiu Boris, Cercueil Jean-Pierre and Krause Denis, Endovascular Therapeutic Embolisation: An Overview of Occluding Agents and their Effects on Embolised Tissues, Current Vascular Pharmacology 2009; 7 (2) . https://dx.doi.org/10.2174/157016109787455617
DOI https://dx.doi.org/10.2174/157016109787455617 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
On the Cellular and Molecular Regulatory Transcriptional Mechanisms and Responsive Putative Pathways to Inflammatory Oxidative Stress Revisited: Current Immunological Breakthroughs and Views at a Glance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Silybin and Silymarin - New and Emerging Applications in Medicine
Current Medicinal Chemistry Amniotic Fluid Stem Cells: a Promising Therapeutic Resource for Cell-Based Regenerative Therapy
Current Pharmaceutical Design A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Anesthesia Issues in Central Nervous System Disorders
Current Aging Science Drug-Induced Pulmonary Hypertension in Newborns: A Review.
Current Vascular Pharmacology Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva.
Current Molecular Medicine Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Molecular Genetics of Familial Exudative Vitreoretinopathy and Norrie Disease
Current Genomics Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Alterations in Homocysteine Metabolism Among Alcohol Dependent Patients - Clinical, Pathobiochemical and Genetic Aspects
Current Drug Abuse Reviews Immunoproteasome in Cancer and Neuropathologies: A New Therapeutic Target?
Current Pharmaceutical Design Current Management of Vascular Tumors in the Neonate
Current Pediatric Reviews NGF and BDNF Alterations by Prenatal Alcohol Exposure
Current Neuropharmacology Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Neuropilin Signalling in Vascular Development and Pathology
Current Angiogenesis (Discontinued)